Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Shumway

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Journal of Cancer|May 3, 2014
Future directions for the early detection of recurrent breast cancerErika J Schneble, Lindsey J Graham, Matthew P Shupe, et al.
JCO Oncology Practice|April 10, 2026
Remote Therapeutic Monitoring and Infection-Related Health Care Resource Utilization in Patients With Hematologic MalignanciesBenjamin A Derman, James H Essell, Mustafa S Ascha, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 2005
Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathwayTimothy C Cheung, Ian R Humphreys, Karen G Potter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrenceE A Mittendorf, A Ardavanis, J Symanowski, et al.
Expert Opinion on Biological Therapy|September 8, 2011
AE37: a novel T-cell-eliciting vaccine for breast cancerAlan K Sears, Sonia A Perez, Guy T Clifton, et al.
Breast Cancer Research and Treatment|April 24, 2020
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrenceTommy A Brown, Elizabeth A Mittendorf, Diane F Hale, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Journal of Cancer|May 3, 2014
Future directions for the early detection of recurrent breast cancerErika J Schneble, Lindsey J Graham, Matthew P Shupe, et al.
JCO Oncology Practice|April 10, 2026
Remote Therapeutic Monitoring and Infection-Related Health Care Resource Utilization in Patients With Hematologic MalignanciesBenjamin A Derman, James H Essell, Mustafa S Ascha, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 2005
Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathwayTimothy C Cheung, Ian R Humphreys, Karen G Potter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrenceE A Mittendorf, A Ardavanis, J Symanowski, et al.
Expert Opinion on Biological Therapy|September 8, 2011
AE37: a novel T-cell-eliciting vaccine for breast cancerAlan K Sears, Sonia A Perez, Guy T Clifton, et al.
Breast Cancer Research and Treatment|April 24, 2020
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrenceTommy A Brown, Elizabeth A Mittendorf, Diane F Hale, et al.
Pageof 7